Literature DB >> 30696330

A Novel Treatment Strategy for Severe Guillain-Barré Syndrome: Zipper Method.

Selman Kesici1,2, Murat Tanyıldız3, Filiz Yetimakman4, Benan Bayrakci2.   

Abstract

OBJECTIVE: Intravenous immunoglobulin and plasma exchange are proven treatments for Guillain-Barré syndrome. Despite these treatments, the prognosis for severe Guillain-Barré syndrome is still not satisfactory. This article seeks for a logical timing for plasma exchange-intravenous immunoglobulin synergy, which may improve outcome in severe Guillain-Barré syndrome requiring mechanical ventilation. STUDY
DESIGN: This study is an open-label study. Nine pediatric severe Guillain-Barré syndrome patients requiring mechanical ventilation were treated with novel treatment strategy named as "zipper method." In this method, following diagnosis of Guillain-Barré syndrome, plasma exchange was started immediately. In the first session of plasma exchange, one and a half volume of patients' plasma was removed by using 5% albumin as replacement solution. At the end of the plasma exchange session, 0.4 g/kg intravenous immunoglobulin infusion was started immediately. Second plasma exchange session was applied with one volume change after 24 hours from the end of the intravenous immunoglobulin infusion. Each plasma exchange session was followed by intravenous immunoglobulin infusions. This plasma exchange-intravenous immunoglobulin cycle was repeated for 5 times.
RESULTS: Among the 9 patients, the mean mechanical ventilation duration was 7 (5-14) days and the mean hospital stay was 18 (10-30) days. Medical Research Council sum score was increased in all patients, especially after the third session. All patients survived and all patients were able to walk unaided on the 28th day of admission.
CONCLUSION: The zipper method as a novel treatment modality seems to reduce mortality, speed up weaning from mechanical ventilation, and shorten hospital stay, with excellent outcome in severe Guillain-Barré syndrome patients, who require intensive care. This technique stands as a promising immunomodulation strategy for various scenarios.

Entities:  

Keywords:  Guillain-Barré syndrome; acute motor axonal neuropathy; intravenous immunoglobulin; pediatric intensive care; plasma exchange; zipper method

Mesh:

Substances:

Year:  2019        PMID: 30696330     DOI: 10.1177/0883073819826225

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  6 in total

1.  Clinical efficacy of high-dose intravenous gammaglobulin in acute Guillain-Barre syndrome and effect on serum concentration of inflammatory factors.

Authors:  Lifeng Lv; Haijuan Xu; Haining Zhang; Qinde Qi
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

Review 2.  Axonal variants of Guillain-Barré syndrome: an update.

Authors:  Pei Shang; Mingqin Zhu; Ying Wang; Xiangyu Zheng; Xiujuan Wu; Jie Zhu; Jiachun Feng; Hong-Liang Zhang
Journal:  J Neurol       Date:  2020-03-05       Impact factor: 4.849

3.  COVID-Lung: The Battlefield.

Authors:  Benan Bayrakci
Journal:  J Pediatr Intensive Care       Date:  2020-09-21

4.  Zipper method is the emerging treatment option for severe Guillain-Barre syndrome related COVID-19.

Authors:  Ozlem Saritas Nakip; Selman Kesici; Benan Bayrakci
Journal:  Autoimmun Rev       Date:  2021-05-08       Impact factor: 9.754

5.  Modified Zipper Method, a Promising Treatment Option in Severe Pediatric Immune-Mediated Neurologic Disorders.

Authors:  Marc Nikolaus; Fabienne Kühne; Anna Tietze; Julia Thumfart; Caroline Kempf; Alexander Gratopp; Ellen Knierim; Petra Bittigau; Angela M Kaindl
Journal:  J Child Neurol       Date:  2022-04-18       Impact factor: 2.363

6.  Case Report: Guillain-Barré Syndrome as Primary Presentation of Systemic Lupus Erythematosus (SLE-GBS) in a Teenage Girl.

Authors:  Elham Beshir; Ernestina Belt; Nidheesh Chencheri; Aqdas Saqib; Marco Pallavidino; Ulrich Terheggen; Abdalla Abdalla; Leal Herlitz; Elsadeg Sharif; Martin Bitzan
Journal:  Front Pediatr       Date:  2022-03-17       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.